GSA Capital Partners LLP Invests $2.22 Million in Zoetis Inc. (NYSE:ZTS)

GSA Capital Partners LLP bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,354 shares of the company’s stock, valued at approximately $2,218,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. First Personal Financial Services acquired a new position in shares of Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis during the third quarter valued at approximately $33,000. Quarry LP raised its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC acquired a new position in Zoetis in the first quarter valued at approximately $43,000. Finally, Fortitude Family Office LLC lifted its holdings in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.4 %

Shares of ZTS opened at $176.16 on Tuesday. The stock has a fifty day simple moving average of $188.15 and a two-hundred day simple moving average of $179.77. The company has a quick ratio of 2.09, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $79.48 billion, a PE ratio of 33.11, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the firm earned $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, equities analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s payout ratio is 32.33%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent research reports. Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Piper Sandler raised their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.